The headline is broadly defensible, but the qualifications matter. Effect sizes vary by population, the strongest claims rest on shorter trials, and credible voices push back on how it's typically framed.
by about 2014 when the first that sort of really interesting everolimus paper was published by John Manik Lloyd clicks teen and others in December of 2014 that was a real real peak to my curiosity that was a paper that showed that the strength of vaccination in healthy subjects who were I believe about age 65 could be augmented by basically a rapamycin analogue
Every Sunday: the week’s new conflicts and verdict changes — and nothing else.
Native comments, Twitter mentions, and Reddit threads about this claim — surfaced together so the conversation isn't fragmented across platforms.
Bookmarking — the dossier-vs-overview split is the right call. Most of the time I want overview; sometimes I want receipts.
Would love a "what would change this verdict" RSS feed. Sign me up if it exists.